In conclusion, JMJD2C and JAK2 cooperatively remodel the epigenome of Hodgkin lymphoma and primary mediastinal B-cell lymphoma, providing the possibility of the discovery of JAK2 and JMJD2C inhibitors for these malignant diseases [47]. Here, KDM4C is linked to B-cell non-Hodgkin lymphoma.